CNBC’s Angelica Peebles and Novo Nordisk CEO Lars Fruergaard Jørgensen join 'Squawk Box' to discuss the company's quarterly ...

Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI ...

Trump's threat of imposing a tariff on Denmark over desires to acquire Greenland has caught the attention of one of the ...

Novo Nordisk (NVO) shares gain after the pharmaceutical company's earnings beat on the bottom and top lines despite warnings ...

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to ...

Lars Fruergaard Jørgensen began his career at Novo Nordisk as an economist in the health care, economy, and planning department more than 30 years ago. He has served as CEO since 2017 ...

Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said on ...

The Introverted CEO: FT Person of the Year: Lars Fruergaard Jørgensen of Novo Nordisk is an introvert. Jørgensen's leadership is marked by thoughtfulness, patience, and a focus on long-term goals.

Operating profit increased by 25% in Danish kroner and by 26% at constant exchange rates (CER) to DKK 128.3 billion.

The most anticipated annual report in Denmark does not disappoint. Denmark’s largest company and leading pharmaceutical ...

American depositary receipts (ADRs) of Novo Nordisk (NVO) jumped over 4% in pre-market trading this morning after reporting a healthy sales ...